Suifeng Liu

Dr. Suifeng Liu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2024 in International Journal of Cardiology
Verified
Journal Article
Open access
CXChen-Chun Xiong
Chen-Chun Xiong
FGFeng Gao
Feng Gao
JZJian-Hui Zhang
Jian-Hui Zhang
YRYang Ruan
Yang Ruan
TGTang-Gang Gao
Tang-Gang Gao
SLSuifeng Liu
Suifeng Liu
Prior research underscores the significant impact of remnant cholesterol (RC) on stroke occurrence due to its proatherogenic and proinflammatory traits. This study aims to explore diverse risks of new-onset stroke associated with RC, considering distinct inflammation levels in the middle-aged and senior population in China. We analyzed 6509 participants from the China Health and Retirement Longitudinal Study (CHARLS) across four waves (2011-2018). We employed a multivariable Cox proportional hazards regression model, incorporated restricted cubic spline techniques, and conducted sensitivity analyses to evaluate the association among RC, high-sensitivity C-reactive protein (hsCRP), and the risk of new-onset stroke. Over 7 years, 540 new-onset strokes occurred. Individuals in the highest quartile of RC levels exhibited a heightened risk of new-onset stroke, with a multivariable-adjusted hazard ratio (HR) peaking at 1.50 (95% confidence interval 1.12-2.00, P for trend = 0.021), showing a non-linear correlation (P nonlinearity = 0.049). High hsCRP alone had an adjusted HR of 1.10 (95% CI 0.87-1.39), compared to 1.40 (95% CI 1.00-1.96) for high RC alone. Additionally, concurrent high RC and hsCRP showed an adjusted HR of 1.43 (95% CI 1.05-1.96). Consistency persisted across various hsCRP thresholds, after adjusting for additional parameters, or excluding chronic diseases in the primary model, reinforcing result robustness. Our findings reveal a substantial and non-linear association between higher baseline RC levels and an elevated risk of new-onset stroke. Moreover, elevated levels of both RC and hsCRP jointly pose the highest risk for new-onset stroke, surpassing the risk associated with each factor individually.

7 July 2023 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
MWMeng-Dan Wang
Meng-Dan Wang
SZShuo Zhang
Shuo Zhang
XLXing-Yang Liu
Xing-Yang Liu
PWPanpan Wang
Panpan Wang
Yifan ZhuYifan Zhu
Yifan Zhu
LWLei Wen
Lei Wen

29 January 2024 in Clinical Cardiology
Verified
Journal Article
Open access
CXChenchun Xiong
Chenchun Xiong
QYQiaoting Yu
Qiaoting Yu
FGFeng Gao
Feng Gao
SLSong Liu
Song Liu
JZJianhui Zhang
Jianhui Zhang
SLSuifeng Liu
Suifeng Liu
Background: After acute coronary syndrome (ACS), inflammation aids healing but may harm the heart. Interleukin (IL)‐18 and IL‐1β are pivotal proinflammatory cytokines released during pyroptosis, a process that initiates and sustains inflammation. This study aimed to evaluate the levels of circulating IL‐18 and IL‐1β during the progression of ACS and to determine their association with subsequent clinical events in ACS patients.Hypothesis: Circulating levels of IL‐18 and IL‐1β are associated with subsequent clinical events in ACS patients.Methods: Employing immunoassays, we examined plasma levels of IL‐1β and IL‐18 in 159 ACS patients and matched them with 159 healthy controls. The primary composite endpoint included recurrent unstable angina, myocardial infarction, heart failure exacerbation, stroke, or cardiovascular death.Results: ACS patients exhibited a significant increase in plasma IL‐18 levels, measuring 6.36 [4.46−9.88] × 102 pg/mL, in contrast to the control group with levels at 4.04 [3.21−4.94] × 102 pg/mL (p < 0.001). Conversely, plasma levels of IL‐1β remained unchanged compared to the control group. Following a 25‐month follow‐up, IL‐18 levels exceeding the median remained an important prognostic factor for adverse clinical events in ACS patients (hazard ratio = 2.37, 95% confidence interval: 1.14−4.91, p = 0.021). Besides, IL‐18 displayed a nonlinear association with adverse clinical events (p nonlinear = 0.044). Subgroup analysis revealed that the correlation between IL‐18 and the risk of adverse clinical events was not significantly affected by factors such as age, sex, history of diabetes, smoking, Gensini score, or ACS type (all p interaction >0.05).Conclusion: IL‐18 appears to hold potential as a predictive marker for anticipating clinical outcomes in patients with ACS.

9 July 2024 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
XDXian-Hua Deng
Xian-Hua Deng
XLXing-Yang Liu
Xing-Yang Liu
YWYi-Hua Wei
Yi-Hua Wei
KWKe Wang
Ke Wang
JZJun-Rong Zhu
Jun-Rong Zhu
LWLei Wen
Lei Wen

31 October 2022 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
SLSuifeng Liu
Suifeng Liu
SLSong Liu
Song Liu
QYQiao-Ting Yu
Qiao-Ting Yu
TGTang-Gang Gao
Tang-Gang Gao
YZYang Zhang
Yang Zhang
FGFeng Gao
Feng Gao
Background: The role of soluble interleukin-1 receptor type 2 (sIL-1R2) in acute myocardial infarction (AMI) remains undocumented. In the present study, we aimed to evaluate the possible associations of sIL-1R2 with left ventricular (LV) function, remodeling and future clinical events in the setting of AMI. Methods: Circulating sIL-1R2 levels were quantified after percutaneous coronary intervention (PCI) on day 1 of hospital admission for 204 AMI patients, and upon enrollment of 204 healthy controls. Echocardiography was conducted in the acute phase and at 12-month follow-up. Adverse clinical events were registered after 12 months. Results: Circulating sIL-1R2 levels were significantly higher in AMI patients than in healthy controls (medians respectively 6652.81 pg/mL, 3799.13 pg/mL, p < 0.0001). AMI patients with sIL-1R2 levels less than the median had a larger proportion of worsened LV ejection fraction [a decrease in LV ejection fraction (LVEF) of more than 10% units] and reduced LVEF (a final LVEF <50%). After multivariate adjustment, sIL-1R2 levels less than the median were associated with an increased risk of worsened LVEF [odds ratio (OR): 3.7, 95% confidence interval (CI): 1.6–8.5, p = 0.002] and reduced LVEF at 12 months (OR: 2.1, 95% CI: 1.1–4.3, p = 0.035). Moreover, low sIL-1R2 levels were associated with an increased risk of having an adverse clinical event during the first 12 months after AMI [hazard ratio (HR): 2.5, 95% CI: 1.0–6.1, p = 0.039]. Conclusions: Low levels of circulating sIL-1R2 were associated with impaired recovery of LV function and adverse clinical outcomes in AMI patients. These findings might contribute to understanding the important role of sIL-1R2 in postinfarction inflammation.

30 November 2023 in International Heart Journal
Verified
Journal Article
Open access
PDF file
TGTang-Gang Gao
Tang-Gang Gao
FGFeng Gao
Feng Gao
WHWei-Bin Huang
Wei-Bin Huang
JCJia-Yi Cai
Jia-Yi Cai
HYHui-Li Yang
Hui-Li Yang
SLSuifeng Liu
Suifeng Liu
The prognosis of patients with nonvalvular atrial fibrillation (NVAF) with a low CHA2DS2-VASc score (0-1) following a stroke is not well studied. In this investigation, stroke risk factors and prognostic markers in low-risk NVAF patients who are nonetheless at risk for stroke were examined.From January 2012 to January 2022, we retrospectively assessed atrial fibrillation (AF) patients at Xiamen University's Zhongshan Hospital for ischemic stroke. Along with a control group of patients with CHA2DS2-VASc scores of 0-1 who weren't suffering from a stroke, patients with CHA2DS2-VASc scores of 0-1 at the time of stroke were included in the study. Using multivariate logistic regression, independent risk factors were identified. To assess the cumulative occurrences of in-hospital mortality in patients with NVAF-related stroke, the Kaplan-Meier method was used.The study included 156 out of 3.237 inpatients with AF-related stroke who had CHA2DS2-VASc ratings of 0-1. Left atrial diameter (LAD) (odds ratio [OR]: 1.858, 95% confidence interval (CI) 1.136-3.036, P = 0.013), D-dimer (OR: 2.569, 95% CI 1.274-5.179, P = 0.008), and NT-proBNP (OR: 4.558, 95% CI 2.060-10.087, P = 0.000) were found to be independent risk factors for stroke in NVAF patients with a low CHA2DS2-VASc score. During hospitalization, nine patients with NVAF-related stroke died. In patients with NVAF-related stroke, NT-proBNP (hazard ratio: 3.504, 95% CI 1.079-11.379, P = 0.037) was an indicator of mortality risk.Patients with NVAF and CHA2DS2-VASc scores of 0-1 had independent risk factors for stroke in the form of LAD, D-dimer, and NT-proBNP. Notably, in low-risk NVAF patients with stroke, NT-proBNP was discovered to be a potent predictor of in-hospital death.